This MedLibrary.org supplementary page on Pyruvate kinase deficiency is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
This article needs additional citations for verification. Please help improve this article by adding reliable references. Unsourced material may be challenged and removed. (August 2008) |
| Pyruvate kinase deficiency Classification and external resources |
|
 |
|
|---|---|
| Phosphoenolpyruvate | |
| ICD-10 | D55.2 |
| ICD-9 | 282.3 |
| OMIM | 266200 |
| DiseasesDB | 11090 |
| MedlinePlus | 001197 |
| eMedicine | med/1980 |
Pyruvate kinase deficiency, also called erythrocyte pyruvate kinase deficiency,[1] is an inherited metabolic disorder of the enzyme pyruvate kinase which affects the survival of red blood cells.
Both autosomal dominant[2] and recessive[3] inheritance have been observed with the disorder.
Pyruvate kinase deficiency is the second most common cause of enzyme-deficient hemolytic anemia, following G6PD deficiency.
Contents |
Causes
A variety of mutations can lead to lowered production, activity, or stability of pyruvate kinase, an enzyme essential to glycolysis. A total lack of this enzyme's activity will be lethal.
Pathophysiology
Because the ability of erythrocytes to manufacture ATP depends on glycolysis, the cells become deficient in energy and unable to maintain the activity of the basolateral Na+/K+-ATPase. This will result in an increase in intracellular [Na+ which will cause water to diffuse passively into the red blood cell (RBC) and will lead to swelling. This swelling will lead to lysis of the RBCs and an increase in plasma bilirubin. The increase in plasma bilirubin will lead to jaundice and the lysis of the RBCs will lead to hemolytic anemia. The buildup of reaction intermediates can also increase the level of 2,3-bisphosphoglycerate (2,3 BPG) in the cells and affect tissue oxygenation. This will cause a "right shift" in the hemoglobin oxygen saturation curve, implying a decreased oxygen affinity for the hemoglobin and earlier oxygen unloading than under normal conditions.
Red blood cells use glycolysis as their sole energy source. In pyruvate kinase deficiency, the last step (phosphoenolpyruvate converted to pyruvate) of glycolsis is unable to occur. A discrepancy between red blood cell energy requirements and ATP generating capacity produces irreversible membrane injury resulting in cellular distortion, rigidity, and lysis. This leads to premature erythrocyte destruction by the spleen and liver.
Treatment
Most affected individuals do not require treatment. Individuals who are most severely affected may die in utero of anemia or may require blood transfusions or splenectomy, but most of the symptomatology is limited to early life and times of physiologic stress or infection.
Treatment can include a blood transfusion or removal of the spleen. Treatment is usually effective in reducing the severity of the symptoms.
References
- ^ Online 'Mendelian Inheritance in Man' (OMIM) 266200
- ^ Etiemble, J; Picat, C; Dhermy, D; Buc, Ha; Morin, M; Boivin, P (Oct 1984). "Erythrocytic pyruvate kinase deficiency and hemolytic anemia inherited as a dominant trait". American journal of hematology 17 (3): 251–60. ISSN 0361-8609. PMID 6475936.
- ^ Carey, Pj; Chandler, J; Hendrick, A; Reid, Mm; Saunders, Pw; Tinegate, H; Taylor, Pr; West, N (Dec 2000). "Prevalence of pyruvate kinase deficiency in northern European population in the north of England. Northern Region Haematologists Group" (Free full text). Blood 96 (12): 4005–6. ISSN 0006-4971. PMID 11186276.
|
|||||||||||||||||||||||||||||||||||
Wikipedia content modification information:
- This page was last modified on 12 October 2008, at 02:58.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Pyruvate kinase deficiency".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.